200 research outputs found
Comparative validation of three contemporary bleeding risk scores in acute coronary syndromes
Background: Hemorrhagic complications are strongly linked with subsequent adverse outcomes in acute coronary syndrome (ACS) patients. Various risk scores
(RS) are available to estimate the bleeding risk in these patients.
Aims: To compare the predictive accuracy of the three contemporary bleeding
RS in ACS.
Methods: We studied 4500 consecutive patients with ACS. For each patient,
the ACTION, CRUSADE, and Mehran et al bleeding RS were calculated. We
assessed their performance either for the prediction of their own major bleeding events or to predict the TIMI serious (major and minor) bleeding episodes
in the overall population, in patients with non-ST elevation ACS (NSTEACS)
and in those with ST-elevation myocardial infarction (STEMI) patients. Calibration
(Hosmer-Lemeshow test) and discrimination (c-statistic) for the three RS were
computed and compared. We used the concept of net reclassification improvement (NRI) to compare the incremental prognostic value of using a particular RS
over the remaining scores in predicting the TIMI serious bleeding.
Results: The best predictive accuracy was obtained by the CRUSADE score either for the prediction of its own major bleeding events (c-statistic=0.80, 0.791,
and 0.81 for the entire sample, for STEMI, and for NSTEACS patients, respectively) or to predict the TIMI serious bleed occurrence (c-statistic=0.741, 0.738,and 0.745 for the whole population, for STEMI and NSTEACS patients, respectively). The lowest bleeding rates observed in patients classified as low risk corresponded to the CRUSADE RS. All scores performed modestly in patients who
did not undergo coronariography (all c-statistic <0.70). The CRUSADE score was
significantly superior to the ACTION model in predicting the TIMI serious bleeding
occurrence in terms of NRI overall and by ACS subgroups (p<0.05). Overall, the
CRUSADE RS exhibited better calibration for predicting the TIMI serious bleeding
compared to the ACTION and Mehran et al scores (Hosmer-Lemeshow p-values
of 0.26, 0.13, and 0.07, respectively).
Conclusion: The CRUSADE score represents, among the more contemporary
bleeding RS, the most accurate and reliable quantitative clinical tool in STEACS
and STEMI patients. We encourage the utilization of the CRUSADE index for
bleeding risk stratification purposes in daily clinical practice and in ACS outcome
studies. The performance of the three more contemporary bleeding RS is modest
in those patients who received conservative management
Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report
Background: Since post-infarction heart failure (HF) determines a great morbidity and mortality, and given the physiopathology implications of advanced glycation end products (AGE) in the genesis of myocardial dysfunction, it was intended to analyze the prognostic value of these molecules in order to predict post-infarction HF development.
Methods: A prospective clinical study in patients after first acute coronary syndrome was conducted. The follow-up period was consisted in 1 year. In 194 patients consecutively admitted in the coronary unit for myocardial infarct fluorescent AGE levels were measured. The association between glycaemic parameters and the development of post-infarction HF were analyzed in those patients. Finally, we identified the variables with independent predictor value by performing a multivariate analysis of hazard ratio for Cox regression.
Results: Eleven out of 194 patients (5.6%) developed HF during follow-up (median: 1.0 years [0.8 - 1.5 years]). Even though basal glucose, fructosamine and glycated haemoglobin were significant predictive factors in the univariate analysis, after being adjusted by confounding variables and AGE they lost their statistical signification. Only AGE (Hazard Ratio 1.016, IC 95%: 1.006-1.026; p<0,001), together with NT-proBNP and the infarct extension were predictors for post-infarction HF development, where AGE levels over the median value 5-fold increased the risk of HF development during follow-up.
Conclusions: AGE are an independent marker of post-infarction HF development risk
Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
Objective: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase and follow-up period.
Methods: A prospective clinical study was performed in patients with debut's ACS. The endpoints were the development of cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366 days, inter-quartile range: 273-519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7±13.0 years, 24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX score.
Results: The mean fluorescent AGEs and sRAGE levels were 57.7±45.1 AU and 1045.4±850.0 pg/mL, respectively. 19 patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction, glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis, whereas fluorescent AGEs was significantly associated with long-term prognosis.
Conclusions: We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high fluorescent AGE levels are associated with more follow-up events
Short- and Long-Term Prognosis of Patients With Takotsubo Syndrome Based on Different Triggers: Importance of the Physical Nature
Background
Takotsubo syndrome (TTS) is an acute reversible heart condition initially believed to represent a benign pathology attributable to its self-limiting clinical course; however, little is known about its prognosis based on different triggers. This study compared short- and long-term outcomes between TTS based on different triggers, focusing on various physical triggering events.
Methods and Results
We analyzed patients with a definitive TTS diagnosis recruited for the Spanish National Registry on TTS (RETAKO [Registry on Takotsubo Syndrome]). Short- and long-term outcomes were compared between different groups according to triggering factors. A total of 939 patients were included. An emotional trigger was detected in 340 patients (36.2%), a physical trigger in 293 patients (31.2%), and none could be identified in 306 patients (32.6%). The main physical triggers observed were infections (30.7%), followed by surgical procedures (22.5%), physical activities (18.4%), episodes of severe hypoxia (18.4%), and neurological events (9.9%). TTS triggered by physical factors showed higher mortality in the short and long term, and within this group, patients whose physical trigger was hypoxia were those who had a worse prognosis, in addition to being triggered by physical factors, including age >70 years, diabetes mellitus, left ventricular eyection fraction <30% and shock on admission, and increased long-term mortality risk.
Conclusions
TTS triggered by physical factors could present a worse prognosis in terms of mortality. Under the TTS label, there could be as yet undiscovered very different clinical profiles, whose differentiation could lead to individual better management, and therefore the perception of TTS as having a benign prognosis should be generally ruled out
Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry
BACKGROUND: The use of potent P2Y12 inhibitors (ticagrelor & prasugrel) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) is a class I recommendation. We performed a sex-specific analysis comparing the difference in efficacy and safety outcomes between ticagrelor and prasugrel in a real-world ACS population.
METHODS: Data from the multicenter REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) for 4424 ACS patients who underwent PCI and were treated with ticagrelor or prasugrel between 2012 to 2016 were analyzed. Mean follow-up was 17±9 months.
RESULTS: After propensity score matching, there was no significant difference in the occurrence of primary endpoint of net adverse cardiac events between ticagrelor and prasugrel in men (HR: 0.94; 95% CI: 0.69-1.29; P=0.71), or women (HR: 1.17; 95% CI: 0.63-2.20; P=0.62; P interaction [sex] = 0.40). Similarly, no differences were found in the occurrence of any of the secondary endpoints (MACE, all cause death, re-infarction, stent thrombosis, BARC major bleeding and BARC any bleeding) between the two P2Y12 groups between men and women.
CONCLUSIONS: In this real-world ACS population, no relative difference in efficacy or safety outcomes were found between ticagrelor and prasugrel between sexes
Fisiopatología y valor pronóstico de los productos de glicación avanzada y su receptor soluble en la insuficiencia cardíaca
Esta investigación pretende analizar las implicaciones fisiopatológicas y
pronósticas de la glicación avanzada en la insuficiencia cardíaca. A través del
registro principal de la investigación (RAICCRO) y de otros estudios
adyacentes (de índole básica y clínica), se pone de manifiesto la relevancia a
nivel clínico y fisiopatológico de los productos de glicación avanzada (AGE) y
su receptor soluble (sRAGE) en la insuficiencia cardíaca crónica. Así se analiza
la relación de ambas moléculas con el pronóstico de dicha enfermedad,
además de su asociación con la enfermedad arterial coronaria, la fibrilación
auricular y la insuficiencia renal
Estudio SHIFT: papel de la ivabradina en la insuficiencia cardiaca y su importancia en la práctica clínica
- …